02.12.2021NANO COLLOQUIA S3 Avinash Vikatakavi
Date and Time: December 2, 2021 - 15.00 ONLINE
25.11.2021Producing electricity from heat losses: engineered in Pisa the first device capable of achieving it in a controlled manner
It is now possible to create a new generation of “smart” thermoelectric systems to generate clea...
23.11.2021il progetto RIMMEL @ MECSPE - Bologna 2021
Si svolgerà martedì 23 novembre, dalle 16.45 alle 17.45 (Sala Concerto c/o Centro Servizi – Bolo...
19.11.2021Graphene as a solid lubricant becomes super-slippery
Cnr Nano researchers in collaboration with Sussex University and Rice University studied the frictio...
17.11.2021International Workshop on Advanced Materials-to-Device Solutions for Synaptic Electronics
CNR Nano and ICN2 organized the
03.11.2021The RIMMEL Project @ l'Europa è qui 2021 – VOTE THE VIDEO ONLINE
The RIMMEL project enters the “Europe is here ...
11.10.2021Quantum computers become an experimental physics laboratory
A quantum computer is a machine designed to do calculations. Now a group of physicists from CnrNano,...
05.10.20212021 Nobel Prize for the discoveries on TRPV1 and PIEZO receptors
The seminal discoveries by this year’s Nobel Laureates have explained how heat, cold and touch can...
home
- 20.05.2021 - NANO Colloquia 2021 in streaming - Mariacristina GagliardiDate and Time: Thursday May 20, 2021 - 11:00 Streaming at: https://meet.google.com/tcu-rsiq-dfb Once connected, please switch off your microphone and camera. If you have questions, please use the chat to ask for attention. Speaker: Mariacristina Gagliardi (NEST, Istituto Nanoscienze-CNR and Scuola Normale Superiore) Title: Polymer nanoparticles for brain targeting Abstract: Krabbe disease (KD) is a lysosomal storage disorder (LSD) caused by a deficient activity of the enzyme galactosylceramidase (GALC). An impaired GALC activity causes increased psycosine (PSY) levels in neural tissues, leading to a widespread degeneration of glial cells and demyelination. While KD causes early mortality (within 2 years after birth), an effective cure is still lacking. The ideal therapeutic approach would be the systemic administration of the enzyme. This approach fails because of the blood brain barrier (BBB) hampering GALC translocation toward the central nervous system (CNS). A winning strategy is to exploit targeted nanovectors capable of inducing GALC transcytosis across the BBB. In the present work, we developed a new delivery platform based on polymeric degradable reversed micelles (RMs) loaded with GALC and targeted to cross the BBB. RMs are produced with the amphiphilic di-block copolymer methoxy polyethylene glycol-block-poly(lactide-co-glycolide) (mPEG-b-PLGA). The copolymer is functionalized with chemical units suitable for the application. RMs are externally crosslinked to improve their physical stability and GALC retention without affecting degradation and biocompatibility. The conjugation of the ligand Angiopep-2 endows RMs with targeting capabilities toward the CNS. RMs opportunely formulated are administered in vivo in the murine model of KD, the Twitcher (TWI) mouse, via retro-orbital administration. Mice are sacrificed at fixed times after the treatment to evaluate the enzymatic activity recovery. Results show high RMs stability, and a good biocompatibility of the administered formulation. Enzymatic activity recovery is around 10% in respect to that measured in healthy mice. This is a suitable value for KD treatment. In conclusion, the developed system shows some potential and could be considered a good candidate for the KD treatment. Host: Fabio Taddei (9038) - fabio.taddei@nano.cnr.it Stefan Heun (9472) - stefan.heun@nano.cnr.it